PipelineHuidaGene has multiple R&D pipelines for ophthalmology and neurology.
-
01Neurology Diseases
MECP2 Duplication Syndrome (MDS)
Huntington's Disease (HD)
Amyotrophic Lateral Sclerosis (ALS)
-
02Ophthalmology Diseases
RPE65 Mutation-Associated Inherited Retinal Dystrophies (RPE65-IRD)
Neovascular Age-related Macular Degeneration (nAMD)
RHO-Associated Retinitis Pigmentosa (RHO-adRP)
-
03Neuromuscular Diseases
-
NovoCrops and HuidaGene enter licensing partnership to expedite gene editing crop developmentJun 11,2024
Learn More
-
HuidaGene and Synthego Announce Licensing Agreement on Next-Generation Gene Editing Enzyme, hfCas12MaxMay 29,2024
Learn More
-
HuidaGene Therapeutics Receives European Medicines Agency Orphan Designation for HG204 to Treat MECP2 Duplication SyndromeMay 06,2024
Learn More